Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 11/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 7/20 | 0.33 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.33 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.33 |
| ▸ | AGXT | P21549 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16018640 | 0.93 | CHRNA7 (0.35) | CHRNA7SLC5A2SLC5A1SSTR1SSTR2 | |
| SCHEMBL16656269 | 0.92 | SLC5A2 (0.40) | CHRNA7SLC5A2SLC5A1SSTR1SSTR2 | |
| SCHEMBL16018651 | 0.92 | SLC5A2 (0.37) | CHRNA7SLC5A2SLC5A1SSTR1SSTR2 | |
| SCHEMBL16018695 | 0.92 | CHRNA7 (0.35) | CHRNA7SLC5A2SLC5A1SSTR1SSTR2 | |
| SCHEMBL16018612 | 0.92 | SLC5A2 (0.36) | CHRNA7SLC5A2SLC5A1SSTR1SSTR2 | |
| SCHEMBL16018609 | 0.92 | SLC5A2 (0.40) | CHRNA7SLC5A2SLC5A1SSTR1SSTR2 | |
| SCHEMBL16018646 | 0.91 | CHRNA7 (0.36) | CHRNA7SLC5A2SLC5A1SSTR1SSTR2 | |
| SCHEMBL16018603 | 0.91 | SLC5A2 (0.41) | CHRNA7SLC5A2SLC5A1SSTR1SSTR2 | |
| SCHEMBL16018673 | 0.91 | SLC5A2 (0.41) | CHRNA7SLC5A2SLC5A1SSTR1SSTR2 | |
| SCHEMBL16018674 | 0.91 | SLC5A1 (0.30) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012412-B2 | Dual SGLT1/SGLT2 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-21 | — | — | US | disclosed |
| US-20140256657-A1 | DUAL SGLT1/SGLT2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256657-A1 | DUAL SGLT1/SGLT2 INHIBITORS | SLC5A1, SLC5A2, GLP1R | CHRNA7 4646/4885SLC5A2 2/4885SLC5A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.